RNA-based Therapeutics

Dr. Sabine Schneider, Faculty of Chemistry and Pharmacy, LMU

Project: With the final breakthrough in RNA-based therapies in 2020, nucleic acids as a class of substances was introduced into medicine, thus initiating a new phase in the development of new drugs and vaccines. Nucleic therapeutics overall expand the spectrum of medically treatable diseases, as impressively demonstrated by the recent market approval of a number of RNA-based drugs for previously incurable diseases. We are part of the Cluster for Nucleic Acid Therapeutics Munich (CNATM) that has the goal to translate the results in fundamental research in the areas RNAs as targets and vaccines, nucleic acid chemistry, delivery technologies, in vivo models to develop nucleic acids across their whole spectra as new therapy and vaccine concepts. Within this cluster we are interested into development and testing of modified oligonucleotides cell based assays against infectious diseases.

Requirements: PhD in Biochemistry, Molecular Biology or related subjects

Position/Salary: TV-L E13 100% - earliest entry date: 01.03.23

Website: https://schneider.cup.uni-muenchen.de/
CNATM: https://www.clusters4future.de/die-zukunftscluster/die-zukunftscluster-der-zweiten-wettbewerbsrunde/cnatm

APPLY NOW